Sarcoidosis n = 113 | Control group n = 22 | p value | |
---|---|---|---|
Age [years] | 52.0 ± 10.8 | 52.7 ± 11.1 | 0.78 |
Female [n (%)] | 51 (45.1%) | 8 (36.4%) | 0.49 |
BMI [kg/m2] | 29.1 ± 4.4 | 26.4 ± 4.7 | 9.10–3 |
Dyspnoea [n (%)] | 58 (60.2%) | 1 (4.6%) | < 10–5 |
Hypertension [n (%)] | 35 (31.0%) | 7 (31.8%) | 1.00 |
Diabetes [n (%)] | 6 (5.3%) | 0 (0.0%) | 0.59 |
Corticosteroids [n (%)] | 64 (56.6%) | 1 (4.6%) | < 10–5 |
ACE-inhibitors [n (%)] | 14 (12.4%) | 4 (18.2%) | 0.49 |
ARBs [n (%)] | 13 (11.5%) | 0 (0.0%) | 0.13 |
β-blockers [n (%)] | 16 (14.2%) | 1 (4.6%) | 0.31 |
Diuretics [n (%)] | 5 (4.4%) | 1 (4.6%) | 1.00 |
Statins [n (%)] | 11 (9.7%) | 1 (4.6%) | 0.69 |
LV EF [%] | 66 ± 7 | 65 ± 5 | 0.29 |